

CORRECTION

Open Access



Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review

Kentaro Nishi¹, Masao Ogura¹, Naotaka Tamai², Masafumi Gima³, Kentaro Ide³, Goro Koinuma², Koichi Kamei¹ and Shuichi Ito^{1,4*}

Correction: *Pediatr Rheumatol* 20, 60 (2022)
<https://doi.org/10.1186/s12969-022-00723-5>

Published online: 05 September 2022

The original publication of this article [1] contained an incorrect author name. The incorrect and correct name are shown below. The original article has been updated.

Author name

- The incorrect author name is: Naofumi Gima
- The correct author name is: Masafumi Gima

Reference

1. Nishi K, et al. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. *Pediatr Rheumatol*. 2022;20:60. <https://doi.org/10.1186/s12969-022-00723-5>.

Author details

¹Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. ²Division of Pulmonology, National Center for Child Health and Development, Tokyo, Japan. ³Division of Critical Care Medicine, National Center for Child Health and Development, Tokyo, Japan. ⁴Department of Pediatrics, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Kanagawa, Yokohama 236-0004, Japan.

The original article can be found online at <https://doi.org/10.1186/s12969-022-00723-5>.

*Correspondence: itoshu@yokohama-cu.ac.jp

⁴ Department of Pediatrics, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Kanagawa, Yokohama 236-0004, Japan

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.